Acadia Pharmaceuticals | ACAD - Ebit

Stock Price
24.75
Daily Change
-1.38 -5.28%
Monthly
-5.35%
Yearly
32.14%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $35.76M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Incyte USD 431.31M 120.49M Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Moderna USD -260M 557M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Pfizer USD 4.57B 1.97B Sep/2025
Prothena USD -39.76M 12.25M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025